MX388054B - Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. - Google Patents

Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Info

Publication number
MX388054B
MX388054B MX2018013347A MX2018013347A MX388054B MX 388054 B MX388054 B MX 388054B MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 388054 B MX388054 B MX 388054B
Authority
MX
Mexico
Prior art keywords
hair loss
janus
jak
deuterated
inhibitors
Prior art date
Application number
MX2018013347A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013347A (es
Inventor
Amanda T Wagner
Colleen E Hamilton
James V Cassella
Hehn Jana Von
Philip B Graham
Vinita Uttamsingh
Virginia Braman
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX388054(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of MX2018013347A publication Critical patent/MX2018013347A/es
Publication of MX388054B publication Critical patent/MX388054B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018013347A 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. MX388054B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (2)

Publication Number Publication Date
MX2018013347A MX2018013347A (es) 2019-09-02
MX388054B true MX388054B (es) 2025-03-19

Family

ID=60203616

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2018013347A MX388054B (es) 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP4424367A3 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR20250070139A (enExample)
CN (1) CN109069493A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241345T1 (hr) 2016-05-04 2024-12-20 Sun Pharmaceutical Industries, Inc. Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak
CN113906032A (zh) * 2019-02-06 2022-01-07 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
EP4236956A1 (en) * 2020-10-28 2023-09-06 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
US20250275977A1 (en) 2022-05-04 2025-09-04 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
US20260021047A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
TWI665200B (zh) 2009-01-15 2019-07-11 英塞特公司 製造ｊａｋ抑制劑之方法及相關中間化合物
PL2635299T3 (pl) * 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PL2830662T3 (pl) 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
ES2867048T3 (es) 2012-06-15 2021-10-20 Concert Pharmaceuticals Inc Derivados deuterados de ruxolitinib
BR112015001839A2 (pt) * 2012-07-30 2017-07-04 Concert Pharmaceuticals Inc ibrutinibe deuterado
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
HRP20241345T1 (hr) 2016-05-04 2024-12-20 Sun Pharmaceutical Industries, Inc. Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak

Also Published As

Publication number Publication date
HRP20241345T1 (hr) 2024-12-20
EP3452039A4 (en) 2019-12-25
DK3452039T3 (da) 2024-10-07
CN109069493A (zh) 2018-12-21
US12076323B2 (en) 2024-09-03
RS66006B1 (sr) 2024-10-31
SI3452039T1 (sl) 2024-12-31
KR102810262B1 (ko) 2025-05-19
ES2988629T3 (es) 2024-11-21
JP2025026895A (ja) 2025-02-26
EP3452039A1 (en) 2019-03-13
MX2023002323A (es) 2023-03-22
PT3452039T (pt) 2024-10-07
US20200222408A1 (en) 2020-07-16
HUE068643T2 (hu) 2025-01-28
MX2023002325A (es) 2023-03-22
MX2023002321A (es) 2023-03-22
AU2017261286A1 (en) 2018-11-22
AU2025213576A1 (en) 2025-08-21
PL3452039T3 (pl) 2024-11-18
KR20250070139A (ko) 2025-05-20
JP2019516684A (ja) 2019-06-20
BR112018072339A2 (pt) 2019-02-19
JP7586868B2 (ja) 2024-11-19
KR20190003711A (ko) 2019-01-09
AU2017261286B2 (en) 2023-03-23
US20190160068A1 (en) 2019-05-30
WO2017192905A1 (en) 2017-11-09
MX2018013347A (es) 2019-09-02
CA3022519A1 (en) 2017-11-09
MX2023002324A (es) 2023-03-22
SMT202400389T1 (it) 2024-11-15
EP4424367A2 (en) 2024-09-04
EP3452039B1 (en) 2024-07-03
FI3452039T3 (fi) 2024-10-02
AU2023201112A1 (en) 2023-03-30
US10561659B2 (en) 2020-02-18
JP7145080B2 (ja) 2022-09-30
AU2023201112B2 (en) 2025-05-08
EP4424367A3 (en) 2024-11-13
JP2022171838A (ja) 2022-11-11
MX2021014175A (es) 2022-01-04
US20240423986A1 (en) 2024-12-26
KR20230086814A (ko) 2023-06-15
LT3452039T (lt) 2024-10-25

Similar Documents

Publication Publication Date Title
MX2023002324A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
EA202190630A1 (ru) Способы комбинированной терапии
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA202091709A1 (ru) Ингибиторы днк-пк
MY205416A (en) Tyk2 inhibitors and uses thereof
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX388470B (es) Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
WO2016109217A3 (en) Btk inhibitors
MX2021013602A (es) Inhibidores de jak.
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
BR112022005608A2 (pt) Inibidores de jak
MX2022001702A (es) Inhibidores de jak.
EA201792676A1 (ru) Ингибиторы jak1
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
GEAP202516658A (en) Ripk1 inhibitors and methods of use